KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
07 Marzo 2024 - 5:30AM
Business Wire
– Planned transition reflects evolution to
commercial company with sebetralstat for HAE –
– NDA filing remains on track for H1 2024;
Europe and Japan filings H2 2024 –
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced that Benjamin L. Palleiko, the Company’s current
President, CBO and CFO, has been appointed as Chief Executive
Officer and a director of the Company, effective immediately. In
conjunction, Andrew Crockett has submitted his resignation as CEO
and a director of the Company. This appointment is the result of a
planned transition as KalVista prepares to become a commercial
entity following the success of the KONFIDENT Phase 3 trial for its
program sebetralstat as the first potential oral, on-demand therapy
for hereditary angioedema (HAE), with a planned US NDA filing in
the first half of this year.
“I welcome Ben to the CEO role at this critical time in
KalVista’s development. His long tenure with the Company positions
us for continued success and allows us to make this seamless
transition,” said Brian J.G. Pereira, MD, Chairman of the KalVista
Board of Directors. “We also thank Andy for his service to the
Company over the years. We look forward to the Company’s continued
growth as it prepares for the potential launch of the first new,
on-demand therapy for HAE in almost a decade.”
“I am excited to take leadership of KalVista as we move to our
next phase, evolving into a commercial organization,” said Ben
Palleiko, Chief Executive Officer of KalVista. “I thank Andy for
all his contributions to the Company since he co-founded it in 2011
and am grateful for his support over the years we have worked
together. Our recent positive Phase 3 data and successful financing
place us in a strong position to make this transition at this time.
I look forward to continuing to advance our plans for sebetralstat
on an accelerated timeline as we seek to launch it broadly for the
benefit of people worldwide who are living with HAE.”
Ben Palleiko joined KalVista in 2016 as Chief Financial Officer
and has been instrumental in supporting the growth and funding of
the Company during its evolution from a UK-based private research
entity to a multinational pre-commercial organization now preparing
multiple regulatory approval filings for sebetralstat as the first
oral, on-demand therapy for HAE. His more than 25 years of industry
experience include a decade as an investment banker followed by
senior executive roles at several private and public biotechnology
companies. Prior to his business career, Ben served on active duty
for seven years in the US Navy as a Naval Aviator flying
carrier-based jet aircraft. He holds an MBA in Finance and MA in
International Relations from the University of Chicago, and a BA in
Quantitative Economics from Tufts University.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and their results, our ability to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307682920/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com Ryan Baker Head, Investor Relations (617)
771-5001 ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfica de Acción Histórica
De May 2023 a May 2024